OncoSign
Overview
OncoSign is a molecular classification tool that assigns tumor samples to predefined oncogenic subtypes using gene expression or multi-omic signatures. In the TCGA breast cancer ILC/IDC analysis, an OncoSign-adapted classifier was used as one of three orthogonal approaches to resolve the molecular identity of histologically mixed IDC/ILC tumors, determining whether they more closely resemble pure ILC or pure IDC at the genomic/transcriptomic level.
Used by
- Applied (as OncoSign-adapted classifier) alongside ISOpure and ElasticNet to assign 88 mixed IDC/ILC breast tumors to ILC-like or IDC-like molecular classes in the TCGA breast cancer multi-platform study (n=817); concordant with the other two classifiers in placing 24/88 cases as ILC-like and 64/88 as IDC-like; CDH1 mutation was the dominant discriminating feature. PMID:26451490
Notes
- Described in Ciriello et al. (2015) as an adaptation of the OncoSign framework for ILC/IDC distinction.
- Three-classifier concordance (OncoSign/ISOpure/ElasticNet) used to increase confidence in mixed-tumor classification calls.
Sources
This page was processed by crosslinker on 2026-05-14.